Evaluation of immuno-inflammatory parameters as predictive biomarkers in critical patients with covid-19
DOI:
https://doi.org/10.21527/2176-7114.2025.50.13831Keywords:
Leukocytes, SARS-CoV-2, Biomarkers, PrognosisAbstract
The SARS-CoV-2 virus, the etiological agent of coronavirus disease 2019 (COVID-19), infects host cells and begins its viral replication process. After the viral incubation period, the disease can lead to symptoms that range from flu-like symptoms to severe forms of disease (such as respiratory failure), posing a risk to life. The exacerbated inflammatory response in COVID-19 is associated with changes in leukocyte (global and differential counts), platelet, and C-reactive protein (CRP) levels, which when evaluated in isolation have lower power to provide an accurate clinical picture. However, blood count ratios such as lymphocyte-to-total leukocyte ratio (L/WBC) and platelet-to-lymphocyte ratio (PLR) can assertively infer the immuno-inflammatory clinical status. The objective of this study was to evaluate whether leukocyte parameters can be used as biomarkers of prognosis and outcome in critically ill COVID-19 patients. A total of 236 patients admitted to the COVID-19 ICU in a medium-sized and highly complex hospital located in the northwest of the state of Rio Grande do Sul were included in the study. The clinical and laboratory parameters evaluated were CRP, L/WBC and PLR, collected at patient admission and outcome. Data were expressed as mean and standard deviation and analyzed using the Student's T test, considering a significance level of 5%. We identified the applicability of PCR, L/WBC and PLR as predictive biomarkers in critically ill COVID-19 patients. Serum concentrations of CRP, L/WBC and PLR can predict the outcome and indicate the prognosis of COVID-19 patients with COVID-19.
References
1. Ribeiro, Edmar Geraldo e cols. Impacto da pandemia de COVID-19 nas internações hospitalares por doenças cardiovasculares em um grande centro urbano brasileiro. Revista da Sociedade Brasileira de Medicina Tropical [online]. 2022, v. 55, suplemento 1 [Acessado em 21 de setembro de 2022], e0264-2021. Disponível em: <https://doi.org/10.1590/0037-8682-0264-2021>. Epub 28 de janeiro de 2022. ISSN 1678-9849. https://doi.org/10.1590/0037-8682-0264-2021. Acesso em: 21 set. 2022.
2. Bergamaschi, Gaetano; Andreis, Federica Borrelli de; aronico, Nicola; Lenti, Marco Vincenzo; Barteselli, Chiara; Merli, Stefania; Pellegrino, Ivan; Coppola, Luigi; Cremonte, Elisa Maria; Croce, Gabriele. Anemia in patients with Covid-19: pathogenesis and clinical significance. Clinical And Experimental Medicine, [S.L.], v. 21, n. 2, p. 239-246, 8 jan. 2021. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s10238-020-00679-4. Acesso em: 14 abr. 2022.
3. Coronavírus. Secretaria da saúde, 2022. Disponível em: https://coronavirus.rs.gov.br/inicial. Acesso em: 07 mai. 2022.
4. Khalid, S. et al. Compreensão atual de um coronavírus emergente usando a abordagem in silico: Síndrome Respiratória Aguda Grave-Coronavírus-2 (SARS-CoV-2). Revista Brasileira de Biologia [online]. 2023, v. 83 [Acessado em 8 de novembro de 2022], e247237. Disponível em: <https://doi.org/10.1590/1519-6984.247237>. Epub 03 de setembro de 2021. ISSN 1678-4375. https://doi.org/10.1590/1519-6984.247237. Acesso em: 08 nov. 2022.
5. Silva, Giordana Maronezzi da et al. Obesidade como fator agravante da COVID-19 em adultos hospitalizados: revisão integrativa. Acta Paulista de Enfermagem [online]. 2021, v. 34, eAPE02321. Disponível em: <https://doi.org/10.37689/acta-ape/2021AR02321>. Epub 15 Mar 2021. ISSN 1982-0194. https://doi.org/10.37689/acta-ape/2021AR02321. Acesso em: 25 jun. 2022.
6. Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, YS, Singh, KP, Chaicumpa, W., Bonilla-Aldana, DK, & Rodriguez-Morales, AJ (2020). Doença de Coronavírus 2019-COVID-19. Revisões de microbiologia clínica , 33 (4), e00028-20. Disponível em: https://doi.org/10.1128/CMR.00028-20 Acesso em: 09 mai. 2022.
7. WONG CHEW, Rosa Maria; MORALES FERNANDEZ, José Antonio. Generalidades, aspectos clínicos e de prevenção sobre COVID-19: México y Latinoamérica. Univ. Med. , Bogotá , v. 62, n. 3, pág. 97-114, setembro de 2021 . Disponível em: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S2011-08392021000300011&lng=en&nrm=iso.Epub em 30 de junho de 2021. Acesso em: 05 mai. 2022.
8. Barreto, Mauricio Lima et al. O que é urgente e necessário para subsidiar as políticas de enfrentamento da pandemia de COVID-19 no Brasil?. Revista Brasileira de Epidemiologia [online]. 2020, v. 23 [Acessado 15 Setembro 2022], e200032. Disponível em: <https://doi.org/10.1590/1980-549720200032>. Epub 22 Abr 2020. ISSN 1980-5497. https://doi.org/10.1590/1980-549720200032. Acesso em: 15 set. 2022.
9. Almeida, Lucivalda Viegas de et al. Results and effects of patients who have recovered from COVID-19: identifying the relationship with risk factors and comorbidities. Ciência & Saúde Coletiva [online]. 2022, v. 27, n. 08 [Accessed 8 December 2022], pp. 2963-2972. Available from: <https://doi.org/10.1590/1413-81232022278.18672021>. Epub 22 July 2022. ISSN 1678-4561. https://doi.org/10.1590/1413-81232022278.18672021. Acesso em: 26 out. 2022.
10. Acar E, Demir A, Yıldırım B, Kaya MG, Gökçek K. The role of hemogram parameters and C-reactive protein in predicting mortality in COVID-19 infection. Int J Clin Pract. 2021 Jul;75(7):e14256. doi: 10.1111/ijcp.14256. Epub 2021 Apr 30. PMID: 33887100; PMCID: PMC8250321. Acesso em: 23 out. 2022.
11. Russo A, Tellone E, Barreca D, Ficarra S, Laganà G. Implication of COVID-19 on Erythrocytes Functionality: Red Blood Cell Biochemical Implications and Morpho-Functional Aspects. Int J Mol Sci. 2022 Feb 16;23(4):2171. doi: 10.3390/ijms23042171. PMID: 35216286; PMCID: PMC8878454. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35216286/. Acesso em: 17 abr. 2022.
12. Brasil, Conselho Nacional da Saúde. Resolução nº 466, de 12 de dezembro de 2012. Disponível em: https://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf. Acesso em: 04 nov. 2022.
13. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, Berger JS. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jun 14;42(23):2270-2279. doi: 10.1093/eurheartj/ehaa1103. PMID: 33448289; PMCID: PMC7928982. Acesso em: 16 ago. 2022.
14. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Acesso em: 12 out. 2022.
15. Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, Ye L, Xiong J, Jiang Z, Liu Y, Zhang B, Yang W. Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019. Clin Infect Dis. 2020 Nov 19;71(16):2174-2179. doi: 10.1093/cid/ciaa641. PMID: 32445579; PMCID: PMC7314209. Acesso em: 03 nov. 2022.
16. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032. Epub 2020 Feb 28. Acesso em: 28 nov. 2022.
17. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-847. doi:10.1002/ajh.25829. Acesso em: 04 dez. 2022.
18. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-690. doi: 10.1080/22221751.2020.1741327B. Acesso em: 27 nov. 2022.
19. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020;58(7):1063-1069. doi: 10.1515/cclm-2020-0240. Acesso em: 03 dez. 2022.
20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Erratum in Lancet. 2020 Feb 15;395(10223):496. doi: 10.1016/S0140-6736(20)30252-X. Epub 2020 Jan 30. Acesso em: 16 nov. 2022.
21. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med. 2020;58 (7):1135-1138. doi:10.1515/cclm-2020-0272 [Epub ahead of print]. Acesso em: 02 dez. 2022.
22. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Acesso em: 18 nov. 2022.
23. Behrens K, Alexander WS. Cytokine control of megakaryopoiesis. Growth Factors. 2018;36(3-4):89-103. doi:10.1080/08977194.2018. 1498487. Acesso em: 04 dez. 2022.
24. Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID-9 and the clinical hematology laboratory. Int J Lab Hematol. 2020 Jun;42 Suppl 1:11-18. First published:20 April 2020 https://doi.org/10.1111/ijlh.13229. Acesso em: 24 nov. 2022.
25. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-768. doi: 10.1093/cid/ciaa248. Epub ahead of print. Acesso em: 29 nov. 2022.
26. Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. [published online ahead of print, 2020 Mar 17]. J Med Virol. 2020;10.1002/jmv.25767. doi:10.1002/jmv.25767. Acesso em: 22 nov. 2022.
27. Rayes J, Bourne JH, Brill A, Watson SP. The dual role of platelet-innate immune cell interactions in thrombo-inflammation. Res Pract Thromb Haemost. 2019;4(1):23-35. Published 2019 Oct 17. doi:10. 1002/rth2.12266. Acesso em: 24 nov. 2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Matias Nunes Frizzo, Vitor Antunes de Oliveira, Gabriel Henrique Schmidt Mattos, Kassandra Cristina Gaklik, Vitória de Oliveira Viland
This work is licensed under a Creative Commons Attribution 4.0 International License.
By publishing in Revista Contexto & Saúde, authors agree to the following terms:
The works are licensed under the Creative Commons Atribuição 4.0 Internacional (CC BY 4.0) license, which allows:
Share — to copy and redistribute the material in any medium or format;
Adapt — to remix, transform, and build upon the material for any purpose, including commercial.
These permissions are irrevocable, provided that the following terms are respected:
Attribution — authors must be properly credited, with a link to the license and indication of any changes made.
No additional restrictions — no legal or technological measures may be applied that restrict the use permitted by the license.
Notes:
The license does not apply to elements in the public domain or covered by legal exceptions.
The license does not grant all rights necessary for specific uses (e.g., image rights, privacy, or moral rights).
The journal is not responsible for opinions expressed in the articles, which are the sole responsibility of the authors. The Editor, with the support of the Editorial Board, reserves the right to suggest or request modifications when necessary.
Only original scientific articles presenting research results of interest that have not been published or simultaneously submitted to another journal with the same objective will be accepted.
Mentions of trademarks or specific products are intended solely for identification purposes, without any promotional association by the authors or the journal.
License Agreement (for articles published from September 2025): Authors retain copyright over their article and grant Revista Contexto & Saúde the right of first publication.
